Chemiax
Traneurocin
Traneurocin
Couldn't load pickup availability
cGP – Research Peptide | 1g
Other names: Cyclic glycine-proline; Cycloprolylglycine; NA-831
Specification:
- CAS: 3705-27-9
- Molar Mass: 54.169 g·mol−1
- Sequence: Cyclo Gly-Pro
- Purity: ≥99%
- Form: Powder
- Amount: 1g per jar
About Traneurocin
Traneurocin (cyclo-gly-pro, cGP) is a stable cyclic dipeptide naturally generated from the N-terminal tripeptide of insulin-like growth factor-1 (IGF-1) and now formulated as the investigational drug NA-831. It has high oral bioavailability. Doses used in investigational studies suggest a dosage range from 10mg a day to 50mg a day, with 10mg/day proposed for mild cognitive impairment and Alzheimer's prevention, and doses in the 30mg-50mg range for mild-to-moderate Alzheimer's disease.
Because it retains the IGF-1 binding motif, cGP competes with IGF-1 for IGF-binding protein-3, boosting the fraction of free, bioactive IGF-1 while itself readily crossing the blood–brain barrier (≈7 h plasma half-life). Pre-clinical pharmacology also shows positive allosteric modulation of AMPA and GABA_A receptors and stimulation of brain-derived neurotrophic factor, aligning with reported neuro-protective, neurogenic and cognition-enhancing actions.
Animal and cellular studies back up these mechanistic claims: cGP limits hydrogen-peroxide–induced oxidative injury in neuronal cultures, reduces infarct volume and improves functional recovery after experimental stroke, enhances spatial learning and synaptic plasticity in rodent tasks, and, in transgenic APP/PS1 mice,lowers amyloid plaque load while rescuing memory deficits. These effects are accompanied by promoted neurogenesis, vascular remodeling, and tempered inflammatory and apoptotic signaling, suggesting a broad cytoprotective profile that converges on IGF-1 normalization and downstream trophic cascades.
Clinically, NA-831 has completed a Phase 1 safety study in mild cognitive impairment and has advanced to Phase 2 trials in Alzheimer’s disease, fragile X and Rett syndromes, Phase 1 in major depressive disorder, and a Phase 3 program targeting COVID-19–associated neuropathy. In parallel, observational work shows that a higher plasma cGP/IGF-1 ratio correlates with better cognition in ageing cohorts and with improved outcomes after ischemic stroke, positioning cGP both as a therapeutic and as a biomarker of IGF-1 bioavailability. To date, reported tolerability is excellent, and no serious adverse signals have emerged, but efficacy data remain preliminary pending completion of the ongoing registrational studies.
Share
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the European Medicines Agency (EMA) to prevent, treat or cure any medical condition, ailment or disease. Please contact us if in need for bulk purchases for larger experiments.
View full details